Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

Rona Yaeger Nataliya V Uboha Meredith S Pelster Tanios S Bekaii-Saab Minal Barve Joel Saltzman Joshua K Sabari Julio Antonio Peguero Andrew Scott Paulson Pasi A Janne Marcia Roxana Cruz-Correa Kenna Anderes Karen Velastegui Xiaohong Yan Hirak Der-Torossian Samuel J Klempner Edmund S Kopetz

Published in: Cancer discovery (2024)

Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer.

Keyphrases

metastatic colorectal cancer
wild type
squamous cell carcinoma
healthcare
locally advanced
small cell lung cancer
palliative care
electronic health record
quality improvement
big data
human health
machine learning
bioinformatics analysis
climate change
affordable care act
rectal cancer
artificial intelligence